EndoVascular Aortic Dissection Early vs Delayed
Condition(s) studied
Investigational drug(s) / intervention(s)
Acute Phase: Patients with acute high-risk type B aortic dissection received endovascular treatment in acute phase (2-14days)
Subacute Phase: Patients with acute high-risk type B aortic dissection received endovascular treatment in subacute phase (≥14days)
Study summary
This is a prospective, multicenter, non-inferior, parallel-controlled observational study. This study aims to compare clinical outcomes of endovascular treatment for acute high-risk type B aortic dissection in the acute phase versus the subacute phase. No interventions will be imposed on the patients' standard treatment. Patients with acute high-risk type B aortic dissection will be grouped based on the actual timing of their treatment.
Eligibility
Primary outcome measure(s)
- 30-day all-cause mortality rate — 30 days following the operation
paraplegia, stroke, new entry tear, renal/liver dysfunction, type I/II/R endoleak - 30-day complication rate — 30 days following the operation
access site complications
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Shanghai Zhongshan Hospital | Shanghai | China |
More Shanghai Zhongshan Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07143071 on ClinicalTrials.gov ↗ ← All trials in China